Products for Research Use Only

Lapatinib ditosylate monohydrate

CAT: 0013-GTR19162300-01Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19162300-01Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lapatinib ditosylate is an anti-Y drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung Y. (In Vitro) :Lapatinib (GW2016; 0.03-10 μM; 6 hours; BT474 and HN5 cells) treatment inhibits receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner. Phosphorylation of serine 473 of AKT was inhibited by GW2016 in a dose-dependent manner.Lapatinib (GW2016; 72 hours; HN5, A-43, BT474, N87, and CaLu-3 cells) treatment has a selective inhibition of the proliferation of human tumor cell lines.Lapatinib (GW2016; 1-10 μM; 72 hours; HN5 cells) treatment results in induces G1 arrest. (In Vivo) :Lapatinib (GW2016; 30-100 mg/kg; oral administration; twice daily; for 21 days; CD-1 nude female mice) treatment inhibits tumor xenograft growth of the HN5 cells in a dose-responsive manner at 30 and 100 mg/kg, with complete inhibition of tumor growth at the higher dose.
CAS Number
388082-78-8
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
Soluble in DMSO
Smiles
O.CC1=CC=C (C=C1) S (O) (=O) =O.CC1=CC=C (C=C1) S (O) (=O) =O.CC1=CC=C (C=C1) S (O) (=O) =O.CC1=CC=C (C=C1) S (O) (=O) =O.CS (=O) (=O) CCNCC1=CC=C (O1) C1=CC2=C (C=C1) N=CN=C2NC1=CC (Cl) =C (OCC2=CC (F) =CC=C2) C=C1.CS (=O) (=O) CCNCC1=CC=C (O1) C1=CC2=C (C=C1) N=CN=C2NC1=CC (Cl) =C (OCC2=CC (F) =CC=C2) C=C1
Molecular Formula
C29H26ClFN4O4S·2 (C7H8O3S) ·H2O
Molecular Weight
943.47
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.